立体定向消融放疗治疗寡转移性肾细胞癌(SABR ORCA):28项研究的荟萃分析
该系统综述与荟萃分析纳入1998至2019年发表的28项研究,共1602例患者、3892个病灶,评估立体定向放疗治疗转移性肾细胞癌的疗效与安全性;1年局部控制率颅外89.1%、颅内90.1%,1年生存率颅外86.8%、颅内49.7%,3-4级毒性颅外0.7%、颅内1.1%,结论认为立体定向放疗安全有效,需进一步前瞻性研究。
要点
- 1年局部控制率颅外89.1%、颅内90.1%。
- 1年生存率颅外86.8%、颅内49.7%。
- 3-4级毒性颅外0.7%、颅内1.1%。
核心结论
- 立体定向放疗对肾细胞癌寡转移安全有效,1年局部控制率约90%,任何显著毒性约1%,需进一步前瞻性研究。
研究设计与样本
- 系统综述与荟萃分析,采用PICOS/PRISMA/MOOSE方案筛选1998至2019年发表的研究,共纳入28项研究、1602例患者(颅外679例/颅内923例)、3892个病灶(颅外1159个/颅内2733个),中位年龄62岁。
主要发现
- 1年局部控制率:颅外89.1%(95%CI 83.6-93.7%,I2=71%),颅内90.1%(95%CI 83.5-95.3%,I2=74%)。
- 1年生存率:颅外86.8%(95%CI 62-99.8%,I2=95%),颅内49.7%(95%CI 41.1-58.3%,I2=74%)。
- 任何3-4级毒性发生率:颅外0.7%(95%CI 0-2.1%,I2=0%),颅内1.1%(95%CI 0-7.4%,I2=53%)。
- 中位治疗体积:颅外59.7cc(四分位距31.1-71.4),颅内2.3cc(四分位距1.3-4.3)。
临床怎么用
- 原文结论认为立体定向放疗对肾细胞癌寡转移安全有效,需进一步前瞻性研究。
局限性
- 原文结论指出需进一步前瞻性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The use of stereotactic ablative radiotherapy for recurrent and metastatic renal cell carcinoma (RCC) is not yet standard treatment due to uncertainties regarding its efficacy and safety. OBJECTIVE: The objective of the systematic review and meta-analysis was to assess the efficacy and safety of stereotactic radiotherapy for metastatic RCC. EVIDENCE ACQUISITION: A Population, Intervention, Control, Outcome, Study Design (PICOS)/Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)/Meta-analysis of Observational Studies in Epidemiology (MOOSE) protocol was utilized to select studies published during 1998-2019. The primary outcome was 1 year local control and 1 year overall survival; the secondary outcome was Common Terminology Criteria for Adverse Events grade 3-4 toxicity. Weighted random-effect meta-analyses were conducted using the DerSimonian and Laird method, heterogeneity was evaluated using the I2 statistic and Cochran Q test, and the Egger test assessed publication bias. EVIDENCE SYNTHESIS: A total of 265 studies were screened and 28 studies were included. There were 1602 mutually exclusive patients (679 extracranial/923 intracranial) and 3892 lesions (1159 extracranial/2733 intracranial). The median age was 62yr. The median treatment volume was 59.7cc for extracranial (interquartile range: 31.1-71.4) and 2.3cc for intracranial (interquartile range: 1.3-4.3) lesions. Under the random-effect model, the summary effect size for 1-yr local control was 89.1% (95% confidence interval [CI]: 83.6-93.7%, I2=71%) and 90.1% (95% CI: 83.5-95.3%, I2=74%) for extracranial and intracranial disease, respectively. The 1-yr survival rates were 86.8% (95% CI: 62-99.8%, I2=95%) and 49.7% (95% CI: 41.1-58.3%, I2=74%) for extracranial and intracranial disease, respectively. The incidence of any grade 3-4 toxicity was 0.7% (95% CI: 0-2.1%, I2=0%) for extracranial disease and 1.1% (95% CI: 0-7.4%, I2=53%) for intracranial disease. CONCLUSIONS: Stereotactic radiotherapy is safe and efficacious for RCC oligometastases, with local control at 90% and any significant toxicity at 1%, reported at 1yr. Further prospective studies are needed. PATIENT SUMMARY: Stereotactic radiotherapy is safe and effective in treating kidney cancer that has spread to other parts of the body: 90% of cancers do not progress in the treated region and <1% of patients have side effects at 1yr.
引用
- Zaorsky NG, Lehrer EJ, Kothari G, et al. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019. PMID: 31302061. doi:10.1016/j.euo.2019.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。